SAVE (Sleep apnea cardiovascular endpoints study) is an investigator-initiated and collaborative, phase III, international, multi-centre, open label, randomised, controlled trial to determine the effects of nasal continuous positive airway pressure (CPAP) in preventing cardiovascular disease in high risk patients with moderate-severe obstructive sleep apnea (OSA).
SAVE in India
More than 20 private and government hospitals across India will aim to recruit 500 patients (10% of the total randomised participants) for this important trial. Patient recruitment in India will commence in the second half of 2009.
Collaborators
SAVE Country Principal Investigator:
Dr.N.Ramakrishnan
Nithra Institute of Sleep Sciences
